Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2007-08-28
2011-12-06
Zeman, Mary (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C702S020000, C703S011000, C707S700000, C436S501000, C435S006100, C435S007100, C536S024100
Reexamination Certificate
active
08073630
ABSTRACT:
Pharmacogenetic methods for determining a predicting responsiveness to antifolate therapy for subjects that present with recent-onset undifferentiated arthritis. The methods are based on the determination of a set of clinical parameter values and determining a predicted responsiveness to antifolate therapy by correlating the parameter values with predefined responsiveness values associated with ranges of parameter values. Parameters values that are decisive for responsiveness to antifolate therapy may include polymorphisms in the methylenetetrahydrofolate dehydrogenase (MTHFD1) gene as well as in three genes involved in the adenosine release pathway, the presence or absence of Rheumatoid factors, gender, pre- or postmenopausal status and/or smoking status.
REFERENCES:
patent: 7702469 (2010-04-01), Huizinga et al.
patent: 7713696 (2010-05-01), Guchelaar et al.
patent: 2009/0029379 (2009-01-01), Guchelaar et al.
patent: 2010/0240541 (2010-09-01), Guchelaar et al.
patent: WO 2005/022118 (2005-03-01), None
Wessels et all 2007 Arthritis and Rheumatism 56, 6, 1756-1775.
Gervaisini 2009 Genes and metabolism, 10, 547-566.
Chan et al.,Molecular action of methotrexate in inflammatory diseases, Arthritis Research, vol. 4 No. 4, 266-273, (2002).
Krajinovic et al.,Role of Polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia, The Pharmacogenomics Journal, vol. 4, 66-72 (2004).
Kalsi et al.,Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation—A Potential Mechanism of Protection in heart failure, Cardiovascular Research, vol. 59, 678-684 (2003).
Dervieux et al.,Polyglutamation of Methotrexate with common Polymorphisms in Reduced Folate Carrier, Aminoimidazole Carboxamide Ribonucleotide Transformylase, and Thymidylate Synthase are associated with methotrexate effects in Rheumatoid Arthritis, Arthritis & Rheumatism, vol. 50 No. 9, 2766-2774 (2004).
Sumi et al.,Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency, Hum Genet, vol. 111, 360-367 (2002).
Wessels et al.,Efficacy and Toxicity of Methotrexate in Early Rheumatoid Arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes, Arthritis & Rheumatism, vol. 54 No. 4, 1087-1095 (2006).
Raganathan et al.,Will pharmacogenetics allow better prediction of methorexate toxicity and efficacy in patients with rheumatoid arthritis?, Ann Rheum. Dis., vol. 62, 4-9 (2002).
Johnston et al.,The Anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules, Clinical Immunology, vol. 114, 154-163 (2005).
Raganathan et al.,Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis, Pharmacogenomics, vol. 5 No. 5, 559-569, (2004).
Hoekstra et al.,Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis, Ann Rheum. Dis. vol. 62, 423-426 (2003).
International Search Report and Written Opinion based on International Application PCT/NL2007/050420, 16 pages, mailed Dec. 3, 2007.
Green et al., “Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope,” Arthritis and Rheumatism 42(10):2184-2188 (1999).
Wessels et al., “Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis,” Arthritis and Rheumatism 54(9):2830-2839 (2006).
Wessels et al., “A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis,” Arthritis and Rheumatism 56(6):1765-1775 (2007).
Guchelaar Hendrik Jan
Huizinga Tom Willem Johannes
Exagen Diagnostics, Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Zeman Mary
LandOfFree
Pharacogenetic method for prediction of the efficacy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharacogenetic method for prediction of the efficacy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharacogenetic method for prediction of the efficacy of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312077